Stockreport

Altimmune Announces Important Additions to its Patent Portfolio for HepTcell and ALT-702 Programs

Altimmune, Inc.  (ALT) 
NASDAQ:AMEX Investor Relations: altimmune.com/investors
PDF GAITHERSBURG, Md., June 05, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biotechnology company, today announced that it has received additi [Read more]